T2 BIOSYSTEMS NEW DL-,001
T2 BIOSYSTEMS NEW DL-,001
Share · US89853L3024 · TTOO · A3EU63 (XNCM)
Overview Financial Indicators
0,13 EUR
-3,23 % -0,004 EUR
Frankfurt (XNAS) · Current prices and charts at MoneyPeak
06.06.2025 19:43

Current Prices from T2 BIOSYSTEMS NEW DL-,001

ExchangeTickerCurrencyLast TradePriceDaily Change
XNAS: NASDAQ
NASDAQ
TTOO
USD
06.06.2025 19:43
0,15 USD
0,16 USD
-3,23 %

Performance

Day Week Month 3 Months 6 Months 1 Year 5 Years
-0,49 % -6,36 % -7,64 % 3,33 % -72,74 % -96,69 % -100,00 %

Company Profile for T2 BIOSYSTEMS NEW DL-,001 Share

T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida, a direct-from-blood test that identifies blood stream infections that causes sepsis and candidemia; T2Bacteria, a direct-from-blood test, which detects bacterial pathogens associated with sepsis; T2Resistance to identify carbapenem resistance genes; and T2SARS-CoV-2 panel to detect SARS-CoV-2 virus. In addition, it is developing T2Biothreat for detection of biothreat pathogens; comprehensive sepsis panel to detect bloodstream infections caused by bacterial and Candida species, and antibiotic resistant markers; T2Cauris to provide direct detection of the emerging superbug Candida auris in patient skin, patient blood, and hospital environmental samples; and T2Lyme, a direct-from-blood test panel designed to run on the T2Dx Instrument to identify the bacteria that cause Lyme disease. The company has collaboration agreements with Canon U.S. Life Sciences, Inc. to develop a diagnostic test panel to detect Lyme disease. T2 Biosystems, Inc. was incorporated in 2006 and is headquartered in Lexington, Massachusetts.

Company Data

Name T2 BIOSYSTEMS NEW DL-,001
Company T2 Biosystems, Inc.
Symbol TTOO
Website https://www.t2biosystems.com
Primary Exchange XNCM Frankfurt
WKN A3EU63
ISIN US89853L3024
Asset Class Share
Sector Healthcare
Industry Medical - Diagnostics & Research
CEO Mr. Craig R. Jalbert CIRA
Country United States of America
Currency EUR
Employees 0,1 T
Address 101 Hartwell Avenue, 02421 Lexington
IPO Date 2014-08-07

Ticker Symbols

Name Symbol
Frankfurt 3T2.F
NASDAQ TTOO

More Shares

Investors who T2 BIOSYSTEMS NEW DL-,001 hold also have the following shares in their portfolio:
NSW TREASURY CORP. 2037
NSW TREASURY CORP. 2037 Bond
PLANT HEALTH CARE
PLANT HEALTH CARE Share
The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.
Imprint Data Protection Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025